Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prevenox is a natural nutritional supplement developed by the Centro Nacional de Investigaciones Científicas (CNIC) in Cuba. Its active ingredient is a purified mixture of high molecular weight aliphatic fatty acids extracted from sugarcane wax (*Saccharum officinarum* L.). Prevenox is primarily indicated for the management of hypercholesterolemia and the prevention and treatment of osteoporosis and osteoarthritis, particularly in middle-aged and elderly populations. The supplement exhibits a multi-faceted pharmacological profile, including antioxidant, lipid-lowering, antiplatelet, and osteoprotective activities. It is commercialized through Laboratorios Dalmer, the commercial entity of CNIC. While its precise molecular targets remain uncharacterized, it is recognized for its ability to modulate lipid profiles and support bone health through natural metabolic pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Prevenox.